In the widely respected Sunday Times Microsoft Tech Track league table for 2005, Abcam secured 39th place nationally for fastest growing unquoted technology companies. This makes Abcam one of the consistently fastest growing companies in the UK as it is the third consecutive year that Abcam has been ranked in the top 40.
Two years to the month after establishing a permanent presence in the US, Abcam tripled the size of its operation by moving to new 3,000 sq ft premises at the same address in Cambridge, Massachusetts. The larger offices enabled the company to expand its office administration, customer and technical services, product storage and dispatch functions in line with continued business growth in the US.
The Queen’s Award for Enterprise has been running since 1966 and is widely recognised as the premier award for business performance in the UK; granted annually for outstanding business achievement. At its first attempt, Abcam was just one of 135 companies across the UK to win one of these coveted awards. Abcam demonstrated excellent year-on-year growth in overseas sales between 2002 and 2004 with 84% of sales during these three years coming from overseas customers. The award is positive proof of the company’s outstanding success as an international business.
Continued growth over the previous two years and anticipated growth in the foreseeable future prompted Abcam to move to new premises on the Cambridge Science Park. The new home is the company’s third on the Science Park, where it has been based since 2000. At 13,000 sq ft the facility is double the size of the previous unit. A significantly larger laboratory area has allowed Abcam to extend both the scope of its product characterisation and further increase the number of products available to customers. The larger premises also means that new members of staff can be recruited to maintain Abcam’s technical and customer service edge in the market place.
International customers, particularly those in the US, benefited from an even faster website service after Abcam transferred its web server to Redbus in London. Furthermore, the relocation (including new hardware and software implementations) will provide greater website stability and uptime, making product and ordering information even more easy to access.
Abcam’s winning ways reached new heights after it secured two awards in the space of a month. Appearing in Deloite’s Regional Technology Fast 50 league table for the third consecutive year, Abcam topped the table on the strength of sales that grew 7,200 % between 1999 and 2003. Less than a month previously, Abcam had, for the second year, been ranked as one of Britain’s fastest growing technology companies in the Sunday Times Microsoft Tech Track 100.
In the widely respected Sunday Times Microsoft Tech Track league table for 2004, Abcam secured 40th place nationally for fastest growing unquoted technology companies. This follows last year’s ranking of 13th.
Jim joined Abcam in 2001 as Technical Director, initially part time then full time from 2003. He has overseen the expansion of Abcam’s bespoke web-based systems.
Jim holds a degree in Computer Science from Christ’s College, Cambridge University. From 1986 to 2003 he worked for Analysys Ltd, a Cambridge based telecoms consultancy, heading up their IT, software and web development initiatives. During this period he also held a number of external non-exec directorships including Workbench Software Ltd, a start-up with a targeted software package for time recording systems and VBN Ltd, a web-based hosting company specialising in business cluster and innovation network solutions.
Simultaneously, Jonathan Milner (PhD) (Abcam’s founder) moves to Abcam Group Chief Executive.
Abcam, and its Cambridge Science Park neighbour Purely Proteins, signed a collaborative deal to commercialise a new scientific frontier – the proteins encoded by the human genome, known collectively as the proteome. The first objective of the collaboration is to purify protein families that are considered to be major therapeutic targets. The availability of specific protein families as screening tools will enable safer and more effective medicines to be discovered and developed. The deal will harness the complementary technologies of the two companies: Purely Proteins’ focus on small molecule drugs and their protein targets is matched by Abcam’s expertise in antibodies and their ability to recognise and define protein landscapes prior to their exploitation in drug discovery.
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
Website by FisherPaul